HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Black men who have sex with men (MSM) Pre-Exposure Prophylaxis (PrEP) Study with Client Centered Care Coordination (C4)Component.
| Condition | Intervention |
|---|---|
|
HIV |
Drug: FTC/TDF |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Pre-Exposure Prophylaxis (PrEP) Initiation and Adherence Among Black Men Who Have Sex With Men (BMSM) in Three U.S. Cities |
- Initiation of PrEP [ Time Frame: 30 months ] [ Designated as safety issue: No ]Documented in either study CRFs or ACASI
- Adherence to PrEP [ Time Frame: 30 months ] [ Designated as safety issue: No ]Adherence will be assessed via self-report (ACASI), PBMCs and plasma concentration
- Adverse events [ Time Frame: 30 months ] [ Designated as safety issue: No ]Graded via DAIDS Toxicity Grading System determined by review of reported adverse events (clinical and laboratory)
- STIs [ Time Frame: 30 months ] [ Designated as safety issue: No ]Rectal and urine GC/CT, and NAAT for syphilis and chlamydia
- Changes in sexual risk-taking behavior [ Time Frame: 30 months ] [ Designated as safety issue: No ]Measured by ACASI assessments
- Initiate or decline PrEP [ Time Frame: 30 months ] [ Designated as safety issue: No ]Refusal rates will be measured by ACASI assessments
- Incident HIV-seroconversions/characteristics [ Time Frame: 30 months ] [ Designated as safety issue: No ]HIV RNA and genotyping will be performed at the NL on samples confirmed to be HIV infected
- Participant perception of care and referral plan [ Time Frame: 30 months ] [ Designated as safety issue: No ]Assessed via interviewer-administered questionnaire
| Estimated Enrollment: | 225 |
| Study Start Date: | June 2013 |
| Estimated Primary Completion Date: | June 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Daily PrEP + coordination of client centered svs
All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
|
Drug: FTC/TDF
All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
|
Detailed Description:
An open label demonstration study with PrEP and Client Centered Care Coordination (C4) to assess the initiation, acceptability, safety, and feasibility of PrEP for Black MSM (BMSM) in three US Cities. A subset of participants will also be recruited to participate in qualitative interviews about facilitators and barriers regarding PrEP. The study will recruit HIV-uninfected BMSM at risk for HIV infection in three US Cities. Enrollment will include those aged 18 and over with an effort to recruit an equal number of BMSM under age 25 and over age 25 with a total of 225 participants (75 per site).
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
BMSM who meet all of the following criteria are eligible for inclusion in this study:
- 18 years of age or older
- No prior HIV diagnosis (self-report)
- Male at birth
High risk for acquiring HIV infection including any one of the following in the previous 6 months:
- Unprotected sex during receptive or insertive anal intercourse with a male partner
Any protected or unprotected:
i. Receptive or insertive anal intercourse with more than three male sex partners ii. Exchange of money, gifts, shelter or drugs for receptive or insertive anal sex with a male partner iii. Receptive or insertive anal sex while under the influence of drugs or alcohol (i.e., high or drunk within two hours of the sex act) according to self-report"
- STI diagnosis (i.e., syphilis, gonorrhea and chlamydia) by self-report
- Willing to provide locator information in accordance with the Study Specific Procedures (SSP) Manual
- Urine dipstick negative or trace for protein and glucose
- Hemoglobin > 11 g/dL, absolute neutrophil count > 750 cells/mm3, and platelet count ≥ 100,000/mm3
Serum creatinine < upper limit of normal (ULN) and calculated creatinine clearance of at least 60 mL/min by the Cockcroft-Gault formula where:
o eCcr in mL/min = [(140 - age in years) x (actual body weight in kg)] / (72 x serum creatinine in mg/dL) Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) < 3 times the upper limit of normal (ULN)
- Total bilirubin < 2.5 ULN
- Hepatitis B surface antigen (HBsAg) negativ
Exclusion Criteria:
BMSM who meet any of the following criteria will be excluded from this study:
- Any reactive or positive HIV test at Screening, even if subsequent testing indicates that the person is HIV-uninfected
- Transgender
- Active or chronic hepatitis B infection (as evidenced by HBsAg, HbsAb, and HbcAb testing)
- Planning to move out of the area or to travel for more than 3 months during the study follow-up period
- Unwilling to adhere to study procedures
- Current participation in any research study via self-report (however, strictly non-HIV centered observational studies are not exclusionary)
- Previous participation in an HIV vaccine study is exclusionary unless documented evidence of enrollment into a placebo arm
- Use of ARV drugs (PrEP or PEP) in the last 60 days
- Prior history of a gastrectomy, colostomy, ileostomy, or any other procedure altering the gastrointestinal tract or drug absorption (provided by self-report, or obtained from medical history or records)
- Receipt of prohibited medications: interleukin therapy, medications with significant nephrotoxic potential (including but not limited to amphotericin B, aminoglycosides, cidofovir, foscarnet and systemic chemotherapy), and medications that may inhibit or compete for elimination via active renal tubular secretion (including but not limited to probenecid) - (provided by self-report, or obtained from medical history or medical records)
- Any condition, that in the opinion of study staff, would make participation in the study unsafe, or interfere with achieving the study objective
Contacts and Locations| United States, California | |
| UCLA Vine Street Clinic | Not yet recruiting |
| Los Angeles, California, United States | |
| Contact: Steven Shoptaw, PhD 310-794-6206 sshoptaw@mednet.ucla.edu | |
| United States, District of Columbia | |
| George Washington University CRS | Not yet recruiting |
| Washington, District of Columbia, United States | |
| Contact: Manya Magnus, PhD, MPH 202-994-3024 manyadm@gwu.edu | |
| United States, North Carolina | |
| UNC CRS | Not yet recruiting |
| Chapel Hill, North Carolina, United States | |
| Contact: Lisa Hightow-Weidman 919-843-0033 lisa_hightow@med.unc.edu | |
| Principal Investigator: | Steven Shoptaw, PhD | UCLA Vice Street Clinic |
| Principal Investigator: | Manya Magnus, PhD, MPH | George Washington University CRS |
| Principal Investigator: | Lisa Hightow-Weidman | UNC CRS |
More Information
No publications provided
| Responsible Party: | HIV Prevention Trials Network |
| ClinicalTrials.gov Identifier: | NCT01808352 History of Changes |
| Other Study ID Numbers: | HPTN 073 |
| Study First Received: | March 5, 2013 |
| Last Updated: | March 7, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by HIV Prevention Trials Network:
|
AE adverse event AIDS acquired immunodeficiency syndrome ALT (SGPT) alanine aminotransferase ART antiretroviral therapy AST (SGOT) aspartate aminotransferase DCF data collection forms DMC Data Monitoring Committee FDA (U.S.) Food and Drug Administration GCP Good Clinical Practice guidelines HB sAg Hepatitis B surface antigen ICH International Conference of Harmonisation |
IND Investigational New Drug Application IRB Institutional Review Board IU International units mg milligram(s) mm3 cubic millimeter(s) PCR polymerase chain reaction SAE serious adverse event µg microgram ULN upper limit of the normal range WB Western Blot |
Additional relevant MeSH terms:
|
Tenofovir disoproxil Tenofovir Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Therapeutic Uses Anti-HIV Agents |
ClinicalTrials.gov processed this record on May 23, 2013